Modulation of anxiety through blockade of anandamide hydrolysis
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“both serotonin and endocannabinoids are involved in stress-related phenotypes, such as anxiety (212).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“the endogenous cannabinoids, such as anandamide, sleep-inducing substance oleamide (211) and palmitoylethanolamide (212), regulate numerous biological processes such as neuronal migration (213), learning, memory (214), pain processing (215), motility (216), and emotional-and reward-related processing (217–219).”
From Epigenetic Modifications in Stress Response Genes Associated With Childhood Trauma (2019) · cites this paper as [212]
In the citing paper
“Nabilone (Cesamet; Valeant Canada, Ltd., Montreal, Canada), an endocannabinoid receptor (CB 1 and CB 2 ) agonist, has been in use in Europe and Canada for over 25 years and was recently granted approval in the United States for the treatment of chemotherapy-induced nausea and vomiting.”
From The Use of a Synthetic Cannabinoid in the Management of Treatment‐Resistant Nightmares in Posttraumatic Stress Disorder (PTSD) (2009) · cites this paper as [12]
In the citing paper
“It has been well established that inhibition of FAAH, and elevation of AEA signaling, can significantly attenuate behavioral indices of fear and anxiety-related behavior in rodents.”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Kathuria et al., 2003
Citations
Cites
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., & Gilula, N. B. (1996) · Nature · doi:10.1038/384083a0 · Cited by 2,125
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J.-C., & Piomelli, D. (1994) · Nature · doi:10.1038/372686a0 · Cited by 1,587
Self-citationMechanisms of emotional arousal and lasting declarative memory.
Cahill, L., & McGaugh, J. L. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01214-9 · Cited by 1,575
A second endogenous cannabinoid that modulates long-term potentiation
Stella, N., Schweitzer, P., & Piomelli, D. (1997) · Nature · doi:10.1038/42015 · Cited by 1,496
Self-citationBrain monoglyceride lipase participating in endocannabinoid inactivation
Dinh, T. P., Carpenter, D., Leslie, F. M., Freund, T. F., Katona, I., Sensi, S. L., Kathuria, S., & Piomelli, D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152334899 · Cited by 1,373
Self-citationCravatt, B. F., Demarest, K., Patricelli, M. P., Bracey, M. H., Giang, D. K., Martin, B. R., & Lichtman, A. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161191698 · Cited by 1,310
Cited by
Items 301–400 of 1,002
Cippitelli, A., Cannella, N., Braconi, S., Duranti, A., Tontini, A., Bilbao, A., de Fonseca, F. R., Piomelli, D., & Ciccocioppo, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1104-0 · Cited by 127
“Several reports indicate that in rodents, increases of brain anandamide levels following reuptake inhibition or metabolic degradation result in a significant anxiolytic-like response and analgesia (Bortolato et al. 2006; Kathuria et al. 2003; Hohmann et al. 2005; Piomelli et al. 2006).”
BackgroundMethodInfluentialSelf-citationMuccioli, G. G., Fazio, N., Scriba, G. K. E., Poppitz, W., Cannata, F., Poupaert, J. H., Wouters, J., & Lambert, D. M. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050977k · Cited by 126
Retrograde Signalling by Endocannabinoids
Vaughan, C. W., & Christie, M. J. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_12 · Cited by 113
Galve‐Roperh, I., Palazuelos, J., Aguado, T., & Guzmán, M. (2009) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-009-0028-y · Cited by 126
“Administration of the eCB reuptake inhibitor AM404 to rodents induces anxiolytic-like effects and, likewise, the inhibition of FAAH by URB597 enhances stress-coping and moodrelated behavior [17, 60].”
BackgroundMoreira, F. A., de Aguiar, D. C., Terzian, A. L. B., Guimarães, F. S., & Wotjak, C. T. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.046 · Cited by 127
Llorente‐Berzal, A., Terzian, A. L. B., Marzo, V. D., Micale, V., Viveros, M., & Wotjak, C. T. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3917-y · Cited by 121
“These long-term effects might be ascribed to enhanced long-term extinction of conditioned fear; however, URB597 is an irreversible inhibitor of FAAH (Kathuria et al. 2003), and FAAH activity is not fully reconstituted 10 days after a single injection of AM3506, another irreversible FAAH inhibitor (Gunduz-Cinar et al.”
BackgroundSpagnolo, P. A., Ramchandani, V. A., Schwandt, M. L., Kwako, L. E., George, D. T., Mayo, L. M., Hillard, C. J., & Heilig, M. (2016) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13210 · Cited by 104
“The putative role of AEA in regulating anxiety was initially demonstrated by the Kathuria and colleagues, who showed that inhibition of AEA-hydrolysis by FAAH resulted in a reduction of anxiety (Kathuria et al., 2003).”
BackgroundBrain activity of anandamide: a rewarding bliss?
Scherma, M., Masia, P., Satta, V., Fratta, W., Fadda, P., & Tanda, G. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0075-x · Cited by 125
A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders
Witkin, J. M., Tzavara, E. T., Davis, R. J., Li, X., & Nomikos, G. G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.10.006 · Cited by 119
Fattore, L., Spano, M. S., Deiana, S., Melis, V., Cossu, G., Fadda, P., & Fratta, W. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.05.003 · Cited by 115
Mileni, M., Kamtekar, S., Wood, D. C., Benson, T. E., Cravatt, B. F., & Stevens, R. C. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.034 · Cited by 109
“Pharmacological studies in rodents and experiments with knock-out mice have demonstrated that blockade of FAAH activity raises endogenous levels of fatty acid amides (2-6).”
BackgroundFAAH and anandamide: is 2-AG really the odd one out?
Marzo, V. D., & Maccarrone, M. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.03.001 · Cited by 118
Regulation of Inflammatory Pain by Inhibition of Fatty Acid Amide Hydrolase
Naidu, P. S., Kinsey, S. G., Guo, T. L., Cravatt, B. F., & Lichtman, A. H. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164806 · Cited by 108
Basavarajappa, B. S., Ninan, I., & Arancio, O. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05685.x · Cited by 108
11 CO bonds made easily for positron emission tomography radiopharmaceuticals
Rotstein, B. H., Liang, S. H., Placzek, M. S., Hooker, J. M., Gee, A. D., Dollé, F., Wilson, A. A., & Vasdev, N. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00310a · Cited by 113
Bedse, G., Hartley, N. D., Neale, E., Gaulden, A. D., Patrick, T. A., Kingsley, P. J., Uddin, M. J., Plath, N., Marnett, L. J., & Patel, S. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.03.002 · Cited by 106
Enhanced endocannabinoid tone as a potential target of pharmacotherapy
Toczek, M., & Malinowska, B. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.04.054 · Cited by 117
King, A. R., Duranti, A., Tontini, A., Rivara, S., Rosengarth, A., Clapper, J. R., Astarita, G., Geaga, J. A., Luecke, H., Mor, M., et al. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.10.017 · Cited by 122
“We further show that MGL inhibition by URB602 occurs through a rapid, noncompetitive and partially reversible mechanism, suggesting that URB602 – unlike O-aryl carbamate FAAH inhibitors such as URB597 [27] – does not covalently modify MGL. SAR studies confirm this possibility, pointing to substituted ureas as a starti…”
BackgroundSelf-citationLin, H.-C., Mao, S.-C., & Gean, P.-W. (2006) · Learning & Memory · doi:10.1101/lm.217006 · Cited by 107
“1997), whereas active inhibitors of fatty acid amide hydrolase (FAAH), which catalyzes endogenous cannabinoid anadamide hydrolysis, induced anxiolytic effects in rats (Kathuria et al. 2003).”
BackgroundBasavarajappa, B. S., Nagre, N. N., Xie, S., & Subbanna, S. (2014) · Hippocampus · doi:10.1002/hipo.22272 · Cited by 117
“We used optimum dose (0.5 mg/kg), which has been shown to block FAAH activity maximally (Kathuria et al., 2003), in all our subsequent experiments.”
BackgroundMethodInfluentialBátkai, S., Rajesh, M., Mukhopadhyay, P., Haskó, G., Liaudet, L., Cravatt, B. F., Csiszár, A., Ungvari, Z. I., & Pacher, P. (2007) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00373.2007 · Cited by 114
“Importantly, neither pharmacological inhibition nor genetic deletion of the enzyme affects CB1-regulated functions such as core body temperature and locomotion (8, 31), suggesting that FAAH may represent an appealing therapeutic target for treating pain and related neurological disorders as well as anxiety, without th…”
BackgroundSolinas, M., Tanda, G., Justinová, Z., Wertheim, C. E., Yaşar, S., Piomelli, D., Vadivel, S. K., Makriyannis, A., & Goldberg, S. R. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114124 · Cited by 118
“, 2001) or pharmacological blockade (Kathuria et al., 2003; Fegley et al., 2005) of FAAH greatly potentiates other behavioral effects of anandamide.”
BackgroundResultInfluentialSelf-citationPanlilio, L. V., Justinova, Z., & Goldberg, S. R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.003 · Cited by 108
“Finally, it should be noted that systemic injection of CB1 agonists would be expected to affect all populations of CB1 receptors, and therefore could produce CB1-mediated effects that are quite different from those produced by FAAH inhibitors or FAAH deletion, which presumably have a more specific effect, magnifying t…”
BackgroundSasso, O., Moreno-Sanz, G., Martucci, C., Realini, N., Dionisi, M., Mengatto, L., Duranti, A., Tarozzo, G., Tarzia, G., Mor, M., et al. (2013) · Pain · doi:10.1016/j.pain.2012.10.018 · Cited by 105
“FAAH inhibitors such as URB597 [16, 30] and URB937 [7] produce significant anti-nociceptive effects in animal pain models [24, 26].”
BackgroundSelf-citationQin, Z., Zhou, X. C., Pandey, N. R., Vecchiarelli, H. A., Stewart, C. A., Zhang, X., Lagace, D. C., Brunel, J. M., Béïque, J.-C., Stewart, A. F. R., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.02.015 · Cited by 112
Gee, D. G., Fetcho, R. N., Jing, D., Li, A., Glatt, C. E., Drysdale, A. T., Cohen, A. O., Dellarco, D. V., Yang, R. R., Dale, A. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600013113 · Cited by 111
“The endocannabinoid system has been associated with anxiety (34, 35), and we have shown that the FAAH A385 variant allele strengthens frontolimbic circuitry, enhances fear extinction, and decreases anxiety-like behaviors in mice and humans during adulthood (14).”
BackgroundThe role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility
Karasu, T., Marczylo, T. H., Maccarrone, M., & Konje, J. C. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmq058 · Cited by 117
“Other proposed transport mechanisms include simple diffusion (Kathuria et al., 2003) or intracellular sequestration of AEA (McFarland et al.”
BackgroundThe contribution of cyclooxygenase‐2 to endocannabinoid metabolism and action
Fowler, C. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707379 · Cited by 102
“…example, mice lacking the enzyme fatty acid amide hydrolase (FAAH) show large increases in brain anandamide (AEA) concentrations, as do animals treated with selective inhibitors of FAAH such as URB597 (30-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate) (Cravatt et al., 2001; Kathuria et al., 2003).”
BackgroundInfluentialAnandamide hydrolysis: a new target for anti-anxiety drugs?
Gaetani, S., Cuomo, V., & Piomelli, D. (2003) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2003.09.005 · Cited by 116
Self-citationSK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance
Nazzaro, C., Greco, B., Cerovic, M., Baxter, P. S., Rubino, T., Trusel, M., Parolaro, D., Tkatch, T., Benfenati, F., Pedarzani, P., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3022 · Cited by 108
Ghafouri, N., Tiger, G., Razdan, R. K., Mahadevan, A., Pertwee, R. G., Martin, B. R., & Fowler, C. J. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705948 · Cited by 118
“However, subsequent studies comparing the sensitivities of cytosolic and pellet AEA metabolism to inhibition by PTMK, AEA, URB597 and arachidonoyl glycine were inconclusive, owing to the very low level (and hence poor activity : blank ratios) of the cytosolic AEA (data not shown).”
BackgroundMethodResultInfluentialSolinas, M., Panlilio, L. V., Tanda, G., Makriyannis, A., Matthews, S. A., & Goldberg, S. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300754 · Cited by 109
Sun, Y., Tsuboi, K., Zhao, L., Okamoto, Y., Lambert, D. M., & Ueda, N. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2005.08.010 · Cited by 115
“Interestingly, URB597 exerted an anxiolytic effect in rat [43].”
BackgroundMethodInfluentialBehavioural and neuroendocrine effects of cannabinoids in critical developmental periods
Viveros, M., Llorente, R., Moreno, E., & Marco, E. M. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00007 · Cited by 110
“…applications of drugs acting at cannabinoid receptors (appetite stimulants, anti-emetic, analgesics in neuropathic pain, cancer, etc.) (Chaperon and Thiébot, 1999; Fuentes et al., 1999; Williamson and Evans, 2000; Cota et al., 2003; Kathuria et al., 2003; Hall et al., 2005; Viveros et al., 2005).”
BackgroundEndocannabinoid system involvement in brain reward processes related to drug abuse
Solinas, M., Yaşar, S., & Goldberg, S. R. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.005 · Cited by 113
“3 mg/kg doses needed to produce significant elevations in brain levels of anandamide (19,71) and potentiate the in vivo effects of systemically administered anandamide (72,73).”
BackgroundGuindon, J., Desroches, J., & Beaulieu, P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706990 · Cited by 100
“However, Kathuria et al. (2003) demonstrated that URB597, a selective FAAH inhibitor that greatly reduced anandamide degradation in the rat brain, had no effect on 2-AG levels.”
BackgroundAkirav, I. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00034 · Cited by 118
Rodgers, R. J., Evans, P. M., & Murphy, A. (2005) · Behavioural Pharmacology · doi:10.1097/00008877-200509000-00013 · Cited by 97
“, 2000), prevention of anandamide hydrolysis by fatty acid amide hydrolase (FAAH) inhibitors produces anxiolytic-like effects in adult and infant rats (Kathuria et al., 2003).”
BackgroundHill, M. N., Kambo, J. S., Sun, J. C., Gorzalka, B. B., & Galea, L. A. M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05061.x · Cited by 106
“Moreover, inhibition of endocannabinoid reuptake or metabolism reliably exhibits antianxiety and antidepressant properties (Kathuria et al., 2003; Gobbi et al., 2005; Hill & Gorzalka, 2005).”
BackgroundCannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions
Mendizábal, V. E., & Adler‐Graschinsky, E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707261 · Cited by 110
“A number of studies have provided evidence that the enzyme inhibitors might be therapeutically useful in the treatment of pain (Cravatt and Lichtman, 2004) and neuropsychiatric disorders such as anxiety (Kathuria et al., 2003).”
BackgroundFowler, C. J., Tiger, G., Ligresti, A., López-Rodríguez, M. L., & Marzo, V. D. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.03.048 · Cited by 101
Hwang, J., Adamson, C. L., Butler, D., Janero, D. R., Makriyannis, A., & Bahr, B. A. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.06.003 · Cited by 110
“Selective FAAH inhibitors and FAAH knockout studies have described the outcome of elevated endogenous signaling through CB1 receptors (Cravatt et al. 2001; Kathuria et al. 2003; Karanian et al. 2005b, 2007).”
BackgroundMagotti, P., Bauer, I., Igarashi, M., Babagoli, M. A., Marotta, R., Piomelli, D., & Garau, G. (2015) · Structure · doi:10.1016/j.str.2014.12.018 · Cited by 100
“…by the psychotropic component Δ9tetrahydrocannabinol in marijuana – and contribute in important ways to the regulation of food intake, stress and pain response, and synaptic function (Kathuria et al., 2003; Hohmann et al., 2005; Di Marzo and Matias, 2005; Di Marzo, 2008; Piomelli and Sasso, 2014).”
Self-citationMammalian enzymes responsible for the biosynthesis of N -acylethanolamines
Hussain, Z., Uyama, T., Tsuboi, K., & Ueda, N. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2017.08.006 · Cited by 101
“Arachidonoylethanolamide (AEA/anandamide, C20:4) has been most extensively studied among NAEs as an endogenous agonist of the cannabinoid receptors CB1 and CB2 [22–24] and is known to induce analgesia [25], neuroprotection [26], hypotension [27] and antianxiety [28], stimulate appetite [29], increase cell proliferatio…”
BackgroundTriphasic blood pressure responses to cannabinoids: do we understand the mechanism?
Malinowska, B., Baranowska‐Kuczko, M., & Schlicker, E. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01747.x · Cited by 100
“The FAAH inhibitor URB597 has to be mentioned here as well (Kathuria et al., 2003).”
BackgroundElevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications
Pertwee, R. G. (2013) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003649 · Cited by 111
Zhang, D., Saraf, A., Kolasa, T., Bhatia, P., Zheng, G. Z., Patel, M., Lannoye, G. S., Richardson, P., Stewart, A., Rogers, J. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.11.009 · Cited by 99
Fatty Acid Amide Hydrolase: A Gate-Keeper of the Endocannabinoid System
Fezza, F., De Simone, C., Amadio, D., & Maccarrone, M. (2008) · Subcellular Biochemistry · doi:10.1007/978-1-4020-8831-5_4 · Cited by 99
“FAAHwas shown to elicit pain and anxiety (Kathuria et al., 2003), without the”
BackgroundDynamic Regulation of the Endocannabinoid System: Implications for Analgesia
Sagar, D. R., Gaw, A. G., Okine, B. N., Woodhams, S. G., Wong, A., Kendall, D. A., & Chapman, V. (2009) · Molecular Pain · doi:10.1186/1744-8069-5-59 · Cited by 110
“Pharmacological inhibition of FAAH is antinociceptive in models of acute and inflammatory pain [124-129].”
BackgroundGarfunkle, J., Ezzili, C., Rayl, T. J., Hochstatter, D. G., Hwang, I., & Boger, D. L. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800136b · Cited by 109
Kaczocha, M., Hermann, A., Glaser, S. T., Bojesen, I. N., & Deutsch, D. G. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509721200 · Cited by 121
Bossong, M. G., van Hell, H. H., Jager, G., Kahn, R. S., Ramsey, N. F., & Jansma, J. M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.06.009 · Cited by 107
“…previously shown reduced anxiety-like behavior after administration of either low doses of exogenous cannabinoid agonists including THC or drugs that enhance levels of endogenous cannabinoids (Kathuria et al., 2003; Marco et al., 2004; Valjent et al., 2002; see for a review Hill et al. (2009)).”
BackgroundA Potent and Selective Inhibitor of KIAA1363/AADACL1 that Impairs Prostate Cancer Pathogenesis
Chang, J. W., Nomura, D. K., & Cravatt, B. F. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.02.008 · Cited by 103
“The selectivity profile of JW480 thus matches those of other carbamate inhibitors of serine hydrolases, such as the FAAH inhibitor URB597 (Kathuria et al., 2003) or the monoacylglycerol lipase inhibitor JZL184 (Long et al., 2009a), which also show excellent specificity for their target enzymes with the exception of so…”
BackgroundInfluentialInvolvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice
Umathe, S. N., Manna, S. S. S., & Jain, N. S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.04.031 · Cited by 110
In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake
de Lago, E., Ligresti, A., Ortar, G., Morera, E., Cabranes, A., Pryce, G., Bifulco, M., Baker, D., Fernández‐Ruíz, J., & Marzo, V. D. (2003) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.11.027 · Cited by 98
La Rana, G., Russo, R., Campolongo, P., Bortolato, M., Mangieri, R. A., Cuomo, V., Iacono, A., Raso, G. M., Meli, R., Piomelli, D., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.100792 · Cited by 97
“, 1996), an intracellular membrane-bound serine hydrolase whose activity is selectively inhibited by the compounds URB597 and OL135 (Kathuria et al., 2003; Lichtman et al., 2004) as well as by a variety of nonselective agents (for review, see Piomelli, 2005).”
BackgroundInfluentialSelf-citationChemical probes to potently and selectively inhibit endocannabinoid cellular reuptake
Chicca, A., Nicolussi, S., Bartholomäus, R., Blunder, M., Aparisi Rey, A., Petrucci, V., Reynoso-Moreno, I. D. C., Viveros-Paredes, J. M., Dalghi Gens, M., Lutz, B., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704065114 · Cited by 96
“FAAH and MAGL inhibitors such as URB597 (11) and JZL184 (12), respectively, have been instrumental to elucidate the role of AEA and 2-AG in rodent models of anxiety and depression (6, 12–14).”
BackgroundInfluentialDiscovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice
Mock, E. D., Mustafa, M. A., Gunduz‐Cinar, O., Çınar, R., Petrie, G. N., Kantae, V., Di, X., Ogasawara, D., Varga, Z. V., Pálóczi, J., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0528-7 · Cited by 103
Marco, E. M., Adriani, W., Llorente, R., Laviola, G., & Viveros, M. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.008 · Cited by 103
Sasso, O., Bertorelli, R., Bandiera, T., Scarpelli, R., Colombano, G., Armirotti, A., Moreno-Sanz, G., Reggiani, A., & Piomelli, D. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.02.012 · Cited by 96
“Preclinical studies have shown that URB597 readily enters the CNS and exerts a combination of anxiolytic, antidepressant and analgesic effects [9, 13, 14].”
BackgroundSelf-citationTherapeutic Potential of Cannabinoids in Psychosis
Leweke, F. M., Mueller, J. K., Lange, B., & Rohleder, C. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.11.018 · Cited by 99
“It was demonstrated that elevations in anandamide by blocking FAAH resulted in multiple CB1R- and/or CB2R-dependent behavioral effects in rodents, including reduction in pain sensation, inflammation, anxiety, and depression (95).”
BackgroundMorena, M., Berardi, A., Colucci, P., Palmery, M., Trezza, V., Hill, M. N., & Campolongo, P. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.305 · Cited by 101
“The endocannabinoid system can be exogenously targeted by means of the FAAH inhibitor URB597 that elevates endogenous levels of AEA (Kathuria et al, 2003), of the MAGL inhibitor JZL184 that elevates endogenous levels of 2-AG (Long et al, 2009; Morena et al, 2015) or by direct cannabinoid receptor…”
BackgroundSelf-citationMonoacylglycerol lipase – a target for drug development?
Fowler, C. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01950.x · Cited by 107
“…it has other functions, as has been demonstrated convincingly in many electrophysiological and behavioural experiments using FAAH inhibitors and FAAH-/- mice (e.g. Kathuria et al., 2003; Manwell et al., 2009; Schlosburg et al., 2009; Bambico et al., 2010; Kinsey et al., 2010; Ramesh et al., 2011).”
BackgroundThe endocannabinoid system and nondrug rewarding behaviours
Fattore, L., Melis, M., Fadda, P., Pistis, M., & Fratta, W. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.020 · Cited by 110
Lack of selectivity of URB602 for 2‐oleoylglycerol compared to anandamide hydrolysis in vitro
Vandevoorde, S., Jonsson, K., Labar, G., Persson, E., Lambert, D. M., & Fowler, C. J. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706971 · Cited by 97
“…selective inhibitors of this enzyme, such as URB597 (30-carbamoyl-biphenyl-3-yl-cyclohexylcarbamate) have been shown to produce potentially useful effects in models of pain and inflammation (see e.g. Kathuria et al., 2003; Holt et al., 2005; Jayamanne et al., 2006 for studies with this compound).”
BackgroundGodlewski, G., Alapafuja, S. O., Bátkai, S., Nikas, S. P., Cinar, R., Offertáler, L., Osei-Hyiaman, D., Liu, J., Mukhopadhyay, B., Harvey-White, J., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.08.013 · Cited by 95
“Pharmacological blockade or genetic ablation of FAAH in mice result in elevated tissue levels of anandamide, as well as CB1 receptormediated reductions in anxiety-like behavior (Kathuria et al., 2003; Moreira et al., 2008), pain sensation (Cravatt et al.”
InfluentialBushlin, I., Gupta, A., Stockton, S. D., Miller, L. K., & Devi, L. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049789 · Cited by 100
A perspective review on fatty acid amide hydrolase (FAAH) inhibitors as potential therapeutic agents
Tripathi, R. K. P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111953 · Cited by 97
Mayo, L. M., Rabinak, C. A., Hill, M. N., & Heilig, M. A. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.07.019 · Cited by 100
“Inhibition of FAAH can prevent stress-induced increases in glutamate release in the BLA (53), and local blockade of FAAH within the BLA can blunt stress-induced activation of the HPA axis, anxiety-like behavior, and fear extinction impairments (55,56).”
Fatty Acid Amide Hydrolase Determines Anandamide-induced Cell Death in the Liver
Siegmund, S., Seki, E., Osawa, Y., Uchinami, H., Cravatt, B. F., & Schwabe, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509706200 · Cited by 103
An anatomical and temporal portrait of physiological substrates for fatty acid amide hydrolase
Long, J. Z., LaCava, M. E. F., Jin, X., & Cravatt, B. F. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m012153 · Cited by 98
Trezza, V., & Vanderschuren, L. J. M. J. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.141069 · Cited by 91
“However, it exerts analgesic-, anxiolytic-, and antidepressant-like effects (Kathuria et al., 2003; Gobbi et al., 2005).”
BackgroundCannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking
Gamaleddin, I., Wertheim, C. E., Zhu, A. Z. X., Coen, K. M., Vemuri, K. V., Makryannis, A., Goldberg, S. R., & Foll, B. L. (2011) · Addiction Biology · doi:10.1111/j.1369-1600.2011.00314.x · Cited by 94
“Neutral CB1 antagonists or approaches targeting the enzyme fatty acid amide hydrolase (Kathuria et al. 2003; Gobbi et al. 2005; Scherma et al. 2008a), which breaks down endocannabinoids, or the endocannabinoid membrane transporter system (Beltramo et al. 1997), may have therapeutic utility, notably…”
BackgroundThe endocannabinoid system as a target for the treatment of cannabis dependence
Clapper, J. R., Mangieri, R. A., & Piomelli, D. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.018 · Cited by 92
“While URB597 is highly selective for FAAH at pharmacologically relevant concentrations (Clapper et al., 2006; Kathuria et al., 2003; Piomelli et al., 2006), several possible off-targets for AM404 have been identified (Nicholson et al., 2003; Zygmunt et al., 2000).”
BackgroundInfluentialSelf-citationThe endocannabinoid system as a target for addiction treatment: Trials and tribulations
Sloan, M. E., Gowin, J. L., Ramchandani, V. A., Hurd, Y. L., & Foll, B. L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.031 · Cited by 104
Blood pressure regulation by endocannabinoids and their receptors
Pacher, P., Bátkai, S., & Kunos, G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.12.005 · Cited by 95
“Recent evidence indicates, however, that targeting the endocannabinoid system by preventing anandamide degradation may not have the same potential for abuse (Kathuria et al., 2003).”
BackgroundOlango, W., Roche, M., Ford, G., Harhen, B., & Finn, D. P. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01478.x · Cited by 105
“, 1999; Vianna and Brandão, 2003), and there is good evidence that endocannabinoid signalling in the PAG plays an important role in the modulation of behavioural responses to unconditioned (Kathuria et al., 2003; Bortolato et al., 2006; Patel and Hillard, 2006; Lafenêtre et al., 2007; Moreira et al., 2007; Lisboa et a…”
BackgroundTambaro, S., & Bortolato, M. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488912798842269 · Cited by 107
“4) has been shown to reduce anxiety-like behaviors in rats, in a rimonabant-sensitive fashion [155,163,215-217].”
BackgroundSchaefer, C., Enning, F., Mueller, J. K., Bumb, J. M., Rohleder, C., Odorfer, T. M., Klosterkötter, J., Hellmich, M., Koethe, D., Schmahl, C., et al. (2014) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0470-8 · Cited by 92
“FAAH inhibition and a resulting increase in anandamide levels have been linked to heighten aversive memory extinction and reduced anxiety levels in animal studies [9, 13].”
BackgroundEndocannabinoid-mediated synaptic plasticity and addiction-related behavior
Sidhpura, N., & Parsons, L. H. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.05.034 · Cited by 92
“Elevation of eCB levels through inhibition of eCB clearance mechanisms produces anxiolytic-like effects in the elevated zero-maze, elevated plus-maze, light-dark transfer test, defensive withdrawal and marble burying tests and the isolation-induced ultrasonic emission test in pups (Bortolato et al., 2006; Braida et al…”
BackgroundThe Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation
Young, A. P., & Denovan‐Wright, E. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.806417 · Cited by 98
“Although both endocannabinoids have effects on analgesia, AEA has greater effects on depression and anxiety whereas 2-AG appears to contribute more to the effects on movement and temperature regulation (Kathuria et al., 2003; Gobbi et al., 2005; Long et al., 2009).”
BackgroundKaranian, D. A., Karim, S. L., Wood, J. T., Williams, J. S., Lin, S., Makriyannis, A., & Bahr, B. A. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.120147 · Cited by 98
“Enhancement of endocannabinoid responses can be achieved with disruption of FAAH activity (Cravatt et al., 2001; Kathuria et al., 2003), as well as through inhibition of the transporter (Giuffrida et al., 2000; Fegley et al., 2004; Karanian et al., 2005b).”
BackgroundFinn, D. P. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.05.011 · Cited by 101
“Thus, systemic administration of the FAAH inhibitors URB597 and URB532 reduced anxiety-related behaviour in the rat elevated zero-maze and isolation-induced ultrasonic vocalisation tests (Kathuria et al., 2003).”
Endocannabinoids, cannabinoids and the regulation of anxiety
Petrie, G. N., Nastase, A. S., Aukema, R. J., & Hill, M. N. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108626 · Cited by 98
Nomura, D. K., & Casida, J. E. (2010) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf101747r · Cited by 94
Possible involvement of the endocannabinoid system in the actions of three clinically used drugs
Fowler, C. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2003.12.001 · Cited by 96
Role of Endocannabinoid Signaling in Anxiety and Depression
Patel, S., & Hillard, C. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/978-3-540-88955-7_14 · Cited by 98
Bailey, C. R., Cordell, E., Sobin, S. M., & Neumeister, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0051-4 · Cited by 89
“Furthermore, inhibiting the metabolism of AEA leads to a reduction of anxiety in rodents [114].”
BackgroundSink, K. S., Segovia, K. N., Sink, J., Randall, P. A., Collins, L. E., Correa, M., Markus, E. J., Vemuri, V. K., Makriyannis, A., & Salamone, J. D. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2009.11.002 · Cited by 86
“…are consistent with previous reports that CB1 receptor tone is generated within the amygdala in response to stressful or anxietyinducing stimuli (Kathuria et al., 2003), and that elevated anandamide levels in mouse amygdala were observed following exposure to a tone that was paired with…”
ResultSagar, D. R., Kendall, D. A., & Chapman, V. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.335 · Cited by 99
“…inflammationinduced hyperalgesia following peripheral administration of the FAAH inhibitor URB597 (30-carbamoyl-biphenyl-3yl-cyclohexylcarbamate) (Kathuria et al., 2003) in the carrageenan model of inflammatory pain, which was accompanied by significantly increased levels of AEA and 2-AG in the…”
BackgroundInfluentialMarzo, V. D., Griinari, M., Carta, G., Murru, E., Ligresti, A., Cordeddu, L., Giordano, E., Bisogno, T., Collu, M., Batetta, B., et al. (2009) · International Dairy Journal · doi:10.1016/j.idairyj.2009.11.015 · Cited by 94
Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase
Keith, J. M., Apodaca, R. L., Xiao, W., Seierstad, M. J., Pattabiraman, K., Wu, J., Webb, M., Karbarz, M. J., Brown, S. M., Wilson, S. M. B., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.081 · Cited by 95
From endocannabinoid profiling to ‘endocannabinoid therapeutics’
Ligresti, A., Petrosino, S., & Marzo, V. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.04.615 · Cited by 106
Modulation of the endocannabinoid system: Neuroprotection or neurotoxicity?
Fowler, C. J., Rojo, M. L., & Rodríguez‐Gaztelumendi, A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.03.021 · Cited by 97
Luchicchi, A., Lecca, S., Carta, S., Pillolla, G., Muntoni, A. L., Yaşar, S., Goldberg, S. R., & Pistis, M. (2010) · Addiction Biology · doi:10.1111/j.1369-1600.2010.00222.x · Cited by 101
Trezza, V., & Campolongo, P. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00100 · Cited by 84
“In particular, indirect cannabinoid agonists have been proposed as anxiolitic and antidepressant agents (Kathuria et al., 2003; Bortolato et al., 2006; Piomelli et al., 2006; Vinod and Hungund, 2006) and have been reported to facilitate extinction of fear memory in rodents (Bitencourt et al., 2008;…”
BackgroundPanagis, G., Mackey, B., & Vlachou, S. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00092 · Cited by 85
Kerr, D. M., Aoife, G., & Roche, M. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.033 · Cited by 93
“, 2009), several studies have revealed that genetic or pharmacological FAAH inhibition elicits only modest (Kathuria et al., 2003) or no effect (Miller et al.”
BackgroundInteraction between cannabinoid compounds and diazepam on anxiety-like behaviour of mice
Naderi, N., Haghparast, A., Saber-Tehrani, A. S., Rezaii, N., Alizadeh, A.-M., Khani, A., & Motamedi, F. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.11.001 · Cited by 90
Serrano, A., Rivera, P., Pavon, F. J., Decara, J., Suárez, J., Rodriguez de Fonseca, F., & Parsons, L. H. (2012) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2011.01686.x · Cited by 83
Metadata
- Authors
- Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., Giustino, A., Tattoli, M., Palmery, M., Cuomo, V., & Piomelli, D.
- Affiliations
- University of California, Irvine (US)
- University of Urbino (IT)
- University of Parma (IT)
- University of Naples Federico II (IT)
- University of Bari Aldo Moro (IT)
- Sapienza University of Rome (IT)
- Corresponding author
- Piomelli, Daniele
- ORCID
- Venue
- Nature Medicine
- Published
- 2002-12-02
- Volume
- 9
- Issue
- 1
- Pages
- 76-81
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241363254
- Cited by
- 1,293
- References
- 45
- Citations by year
- 2026: 10 · 2025: 23 · 2024: 25 · 2023: 35 · 2022: 34 · 2021: 32 · 2020: 48 · 2019: 45 · 2018: 35 · 2017: 45 · 2016: 59 · 2015: 76 · 2014: 66 · 2013: 72 · 2012: 70
- FWCI
- 29.07
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- anandamide, fatty acid amide hydrolase inhibition, anxiety, CB1 receptor, endocannabinoids, anxiolytics, benzodiazepine-like effects, elevated zero maze
- MeSH terms
- Rimonabant, Fatty Acid Amide Hydrolases, Amidohydrolases, Animals, Anxiety, Arachidonic Acids, Behavior, Animal, Cannabinoids, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Neurons, Piperidines, Pyrazoles, Radioligand Assay, Receptors, Drug, Anti-Anxiety Agents, Vocalization, Animal, Molecular Structure, Rats, Wistar, Receptors, Cannabinoid, Rats, Polyunsaturated Alkamides, Endocannabinoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.